Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Daré Bioscience, Inc. to Present at the H.C. Wainwright 20th Annual Global Investment Conference
Update on recent discussions with the FDA on the Topical 5% Sildenafil Citrate Cream for Female Sexual Arousal Disorder, and on other protofolio programs SAN DIEGO , Aug. 30, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today
View HTML
Toggle Summary Daré Bioscience, Inc. to Present at the Canaccord Genuity 38th Annual Growth Conference
SAN DIEGO , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that John Fair , Chief Business Officer, will present at the Canaccord Genuity 38th Annual Growth Conference on Thursday, August 9, 2018 at 1:00
View HTML
Toggle Summary Daré Bioscience, Inc. Announces Asset Transfer Agreement with Hydra Biosciences, Inc. for CatSper Contraceptive Target
CatSper antagonist has potential to provide pregnancy prevention via administration to either women or men as a novel, rapidly reversible, non-hormonal contraceptive SAN DIEGO , July 16, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience , Inc.  (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical
View HTML
Toggle Summary Daré Bioscience, Inc. Expands Leadership Team, Appointing David Friend, Ph.D. to Chief Scientific Officer
SAN DIEGO , June 06, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.  (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced the appointment of David Friend , Ph.D., to the newly created role of Chief Scientific Officer (CSO). “We are excited to add Dr.
View HTML
Toggle Summary Daré Bioscience, Inc. Expands Leadership Team, Appointing Mary Jarosz, RPh, to Global Head of Regulatory Affairs
SAN DIEGO , June 04, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.  (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced the appointment of Mary Jarosz , RPh, to the newly created role of Global Head of Regulatory Affairs.
View HTML
Toggle Summary EY Announces that Sabrina Martucci Johnson, CEO of Daré Bioscience, Inc., is an Entrepreneur Of The Year® 2018 Award Finalist in San Diego
SAN DIEGO , May 16, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.  (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company focused on women’s sexual and reproductive health, announced today that President and CEO Sabrina Martucci Johnson is a finalist for the Entrepreneur Of The Year ®
View HTML
Toggle Summary Daré Bioscience, Inc. Announces Trial Initiation for Ovaprene® Non-Hormonal Monthly Contraceptive Candidate
SAN DIEGO , May 15, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.  (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company focused on women’s sexual and reproductive health, announced today the initiation of its post-coital test (PCT) clinical trial for its lead product candidate
View HTML
Toggle Summary Daré Bioscience, Inc. Expands Leadership Team, Appointing John Fair to Chief Business Officer
SAN DIEGO , May 08, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced it has appointed Mr. Fair to the newly created position of Chief Business Officer. Mr. Fair’s role will include business and corporate development,
View HTML
Toggle Summary Daré Bioscience, Inc. Enters into Agreement to Acquire Product to Address Vulvar and Vaginal Atrophy in Hormone Receptor-Positive Breast Cancer Patients
Agreement intends to broaden Company’s product portfolio within women’s reproductive health with novel clinical candidate, positioning Company with first in class candidates in contraception, sexual health and vaginal health SAN DIEGO , May 07, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.
View HTML
Toggle Summary Daré Bioscience announces funding award to further the development of Ovaprene™ from the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
SAN DIEGO , April 30, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.  (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it received a Notice of Award for the first $224,665 of the anticipated $1.9 million in grant funding from the Eunice Kennedy Shriver
View HTML